SG155187A1 - Compounds for proteasome enzyme inhibition - Google Patents

Compounds for proteasome enzyme inhibition

Info

Publication number: SG155187A1
Authority: SG; Singapore
Prior art keywords: compounds; peptide; based compounds; activities; ntn
Prior art date: 2004-08-06

Application number

SG200905204-4A

Other languages

English (en)

Inventor

Mark S Smyth

Guy J Laidig

Original Assignee

Proteolix Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-06

Filing date

2005-08-08

Publication date

2009-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35502451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG155187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-08 Application filed by Proteolix Inc filed Critical Proteolix Inc

2009-09-30 Publication of SG155187A1 publication Critical patent/SG155187A1/en

Links

150000001875 compounds Chemical class 0.000 title abstract 6
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title abstract 2
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title abstract 2
230000005764 inhibitory process Effects 0.000 title 1
230000000694 effects Effects 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 abstract 1
108090000604 Hydrolases Proteins 0.000 abstract 1
102000004157 Hydrolases Human genes 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000037012 chymotrypsin-like activity Effects 0.000 abstract 1
150000002118 epoxides Chemical class 0.000 abstract 1
238000007306 functionalization reaction Methods 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
230000035407 negative regulation of cell proliferation Effects 0.000 abstract 1
239000012038 nucleophile Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)

SG200905204-4A 2004-08-06 2005-08-08 Compounds for proteasome enzyme inhibition SG155187A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US59940104P	2004-08-06	2004-08-06
US61000104P	2004-09-14	2004-09-14
US11/106,879 US7232818B2 (en)	2004-04-15	2005-04-14	Compounds for enzyme inhibition

Publications (1)

Publication Number	Publication Date
SG155187A1 true SG155187A1 (en)	2009-09-30

Family

ID=35502451

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201701794UA SG10201701794UA (en)	2004-08-06	2005-08-08	Compounds for proteasome enzyme inhibition
SG200905204-4A SG155187A1 (en)	2004-08-06	2005-08-08	Compounds for proteasome enzyme inhibition

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10201701794UA SG10201701794UA (en)	2004-08-06	2005-08-08	Compounds for proteasome enzyme inhibition

Country Status (24)

Country	Link
US (12)	US7232818B2 (fr)
EP (4)	EP2266999B1 (fr)
JP (2)	JP4743720B2 (fr)
KR (3)	KR20130080064A (fr)
CN (1)	CN102286070B (fr)
AT (1)	ATE496062T1 (fr)
AU (1)	AU2005271232B2 (fr)
BR (2)	BRPI0514102B8 (fr)
CA (1)	CA2589765C (fr)
CY (3)	CY1116771T1 (fr)
DE (1)	DE602005026019D1 (fr)
DK (2)	DK1781688T3 (fr)
ES (2)	ES2525248T3 (fr)
FR (1)	FR16C0017I2 (fr)
HU (2)	HUE038005T2 (fr)
IL (3)	IL181127A (fr)
LT (2)	LT3101026T (fr)
LU (1)	LU93015I2 (fr)
NO (2)	NO341015B1 (fr)
PL (2)	PL1781688T3 (fr)
PT (2)	PT3101026T (fr)
SG (2)	SG10201701794UA (fr)
SI (2)	SI1781688T1 (fr)
WO (1)	WO2006017842A1 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7176232B2 (en)	2002-06-24	2007-02-13	The Regents Of The University Of California	Salinosporamides and methods for use thereof
US7232818B2 (en) *	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
US8198270B2 (en) *	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
WO2005105827A2 (fr)	2004-04-15	2005-11-10	Proteolix, Inc.	Composes pour l'inhibition enzymatique
US8088741B2 (en) *	2004-05-10	2012-01-03	Onyx Therapeutics, Inc.	Compounds for enzyme inhibition
US20050256324A1 (en) *	2004-05-10	2005-11-17	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
EP1830838B1 (fr)	2004-12-03	2012-10-03	Dana-Farber Cancer Institute, Inc.	Compositions et procedes destines au traitement des maladies neoplastiques
HUE027850T2 (en) *	2004-12-07	2016-11-28	Onyx Therapeutics Inc	Preparation for proteasome inhibition
RU2453556C2 (ru)	2005-11-09	2012-06-20	Протеоликс, Инк.	Соединения для ингибирования фермента
RU2450016C2 (ru)	2006-06-19	2012-05-10	Протеоликс, Инк.	Пептидные эпоксикетоны для ингибирования протеасомы
EP2040694A2 (fr) *	2006-07-14	2009-04-01	VIB vzw	Utilisation d'agonistes des ppar-alpha pour le traitement de troubles du dépérissement des muscles squelettiques
US7642369B2 (en) *	2006-09-12	2010-01-05	University Of Kentucky Research Foundation	Epoxyketone-based immunoproteasome inhibitors
AU2013203566B2 (en) *	2007-10-04	2016-10-13	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2016231532B2 (en) *	2007-10-04	2018-05-10	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
KR20170040374A (ko) *	2007-10-04	2017-04-12	오닉스 세라퓨틱스, 인크.	결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US8394816B2 (en) *	2007-12-07	2013-03-12	Irene Ghobrial	Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (fr)	2008-02-11	2009-08-12	Institut National De La Sante Et De La Recherche Medicale (Inserm)	PSMB10 : marqueur de diagnostic et cible thérapeutique de rejet chronique
US7635773B2 (en)	2008-04-28	2009-12-22	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions
WO2009140287A1 (fr) *	2008-05-12	2009-11-19	Nereus Pharmaceuticals, Inc.	Dérivés de salinosporamide à utiliser en tant qu'inhibiteurs des protéasomes
AU2009308516B2 (en)	2008-10-21	2016-08-25	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones
AR075899A1 (es)	2009-03-20	2011-05-04	Onyx Therapeutics Inc	Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US20110009332A1 (en) *	2009-07-09	2011-01-13	Southwest Research Institute	Therapeutic Treatment Of Wounds
GB0914883D0 (en)	2009-08-26	2009-09-30	Univ Belfast	Compound
JP5919196B2 (ja)	2009-11-13	2016-05-18	オニキスセラピューティクス，インク．ＯｎｙｘＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (fr)	2010-03-01	2019-08-20	Onyx Therapeutics, Inc.	Composes pour inhibition de l'immunoproteasome
NZ602872A (en)	2010-04-07	2014-05-30	Onyx Therapeutics Inc	Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en)	2010-09-07	2015-09-08	Northwestern University	Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
WO2012135528A2 (fr)	2011-03-29	2012-10-04	Texas Tech University System	Polythérapie par galectine-3c pour cancer humain
WO2013009923A1 (fr) *	2011-07-13	2013-01-17	Creighton University	Procédés de favorisation de la croissance de neurones
CA2855368A1 (fr)	2011-11-11	2013-05-16	Millennium Pharmaceuticals, Inc.	Biomarqueurs de la sensibilite vis-a-vis d'inhibiteurs du proteasome
CN104039328B (zh)	2011-11-11	2018-10-09	米伦纽姆医药公司	对蛋白酶体抑制剂的反应的生物标记
JP6215235B2 (ja)	2012-01-24	2017-10-18	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	癌の治療方法
DK3702374T3 (da)	2012-02-15	2022-06-27	Cydex Pharmaceuticals Inc	Fremsgangsmåde til fremstilling for cyclodextrin-derivater
KR20200130748A (ko)	2012-05-08	2020-11-19	오닉스 세라퓨틱스, 인크.	펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
JP2015524394A (ja)	2012-07-09	2015-08-24	オニキスセラピューティクス，インク．ＯｎｙｘＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
WO2014015027A1 (fr)	2012-07-18	2014-01-23	Onyx Therapeutics, Inc.	Compositions liposomales d'inhibiteurs du protéasome à base d'époxycétone
CA2881986A1 (fr) *	2012-08-21	2014-02-27	Fluorinov Pharma Inc.	Composes tetrapeptidiques a base d'epoxycetone fluoree et leurs utilisations en tant qu'inhibiteur du proteasome
WO2014066274A1 (fr)	2012-10-22	2014-05-01	Cydex Pharmaceuticals, Inc.	Compositions de cyclodextrine alkylée et procédés de préparation et d'utilisation de celles-ci
JP6279065B2 (ja)	2013-03-13	2018-02-14	サノフイ	抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
ES2687368T3 (es)	2013-03-14	2018-10-24	Onyx Therapeutics, Inc.	Inhibidores de proteasa de epoxi cetona dipeptídica y tripeptídica
AR095426A1 (es)	2013-03-14	2015-10-14	Onyx Therapeutics Inc	Inhibidores tripeptídicos de la epoxicetona proteasa
MX372671B (es)	2013-07-19	2020-04-23	Onyx Therapeutics Inc	Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
CN103360348B (zh) *	2013-07-25	2015-06-24	苏州鹏旭医药科技有限公司	一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CN105518019A (zh) *	2013-09-06	2016-04-20	桑多斯股份公司	肽环氧基酮的合成
US20160194354A1 (en) *	2013-09-06	2016-07-07	Sandoz Ag	Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
WO2015121769A1 (fr)	2014-02-13	2015-08-20	Ranbaxy Laboratories Limited	Procédé pour la préparation de méthyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phénylalaninate
CN103864889B (zh) *	2014-04-04	2017-01-11	重庆泰濠制药有限公司	环氧酮化合物、其制备方法及卡非佐米的制备方法
JP6914188B2 (ja)	2014-08-22	2021-08-04	サイデックス・ファーマシューティカルズ・インコーポレイテッド	分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
WO2016046843A1 (fr)	2014-09-24	2016-03-31	Biophore India Pharmaceuticals Pvt. Ltd.	Procédé pour la préparation de (s)-4-méthyl-n- ((s)-1-(((s)-4-méthyl-1-((r)-2-méthyloxiran-2-yl)-1-oxo-pentan-2-yl)amino)-1-oxo-3-phénylpropan-2-yl)-2-((s)-2-(2-morpholinoacétamido)-4-phénylbutanamido) pentanamide
US20160115198A1 (en)	2014-10-27	2016-04-28	Apicore Us Llc	Methods of making carfilzomib and intermediates thereof
CN104402973A (zh) *	2014-11-24	2015-03-11	重庆泰濠制药有限公司	一种卡非佐米无定型晶的制备方法
EP3227312B1 (fr)	2014-12-02	2019-05-29	Fresenius Kabi Oncology Limited	Procédé de purification de carfilzomib
EP3240575A4 (fr)	2014-12-31	2018-07-25	Dr. Reddy's Laboratories Ltd.	Co-cristal de carfilzomib avec de l'acide maléique et procédé pour la préparation de carfilzomib pur
WO2016170544A1 (fr) *	2015-04-22	2016-10-27	Msn Laboratories Private Limited	Procédé de préparation de (2s)-n-((s)-1-((s)-4-méthyl-1-((r)-2-méthyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phényléthyl)-2-((s)-2-(2-morpholino acétamido)-4-phénylbutanamido)-4-méthylpentanamide
WO2016185450A1 (fr)	2015-05-21	2016-11-24	Laurus Labs Private Limited	Procédé perfectionné de préparation de carfilzomib ou de sels pharmaceutiquement acceptables de celui-ci
CN106317188A (zh) *	2015-06-18	2017-01-11	重庆医药工业研究院有限责任公司	一种制备卡非佐米无定型物的方法
WO2017032487A1 (fr)	2015-08-27	2017-03-02	Technische Universität München	Inhibiteur de protéasome comprenant une fraction d'émission de signal
WO2017098532A1 (fr)	2015-12-11	2017-06-15	Mylan Laboratories Limited	Formes cristalline et amorphe de carfilzomib
TWI636052B (zh) *	2015-12-31	2018-09-21	中化合成生技股份有限公司	無定形卡非佐米(i)的製備方法
US11306107B2 (en)	2016-02-25	2022-04-19	Amgen Inc.	Compounds that inhibit MCL-1 protein
TWI759301B (zh) *	2016-05-24	2022-04-01	美商安美基公司	聚乙二醇化卡非佐米化合物
WO2018024645A1 (fr)	2016-08-02	2018-02-08	Synthon B.V.	Procédé de fabrication du carfilzomib
PH12019500232B1 (en)	2016-08-05	2023-11-15	Amgen Inc	Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof
CN109689635A (zh)	2016-09-14	2019-04-26	费森尤斯卡比肿瘤学有限公司	一种用于纯化卡非佐米中间体的方法
EP3512602B1 (fr)	2016-09-16	2024-03-27	HSF Pharmaceuticals	Inhibiteurs des facteurs de choc thermique (hsf) et utilisations de ceux-ci
EP3330260A1 (fr)	2016-12-01	2018-06-06	Enantia, S.L.	Procédé pour la préparation d'un intermédiaire pour la synthèse de i.a. carfilzomib
JP2020533382A (ja)	2017-09-14	2020-11-19	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	癌の組合せ治療
JP2021503441A (ja)	2017-11-16	2021-02-12	アムジエン・インコーポレーテツド	Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物
CN117051096A (zh) *	2017-12-08	2023-11-14	神经Gx有限责任公司	用于阿尔茨海默病的同步化细胞周期基因表达测试及相关治疗方法
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
CA3043103C (fr) *	2017-12-30	2021-02-09	Unity Biotechnology	Inhibiteurs de proteasome fonde sur un peptide pour le traitement de troubles medies par des cellules senescentes et le traitement du cancer
US10689416B2 (en)	2017-12-30	2020-06-23	Unity Biotechnology, Inc.	Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
US20210276952A1 (en) *	2018-06-22	2021-09-09	Ucl Business Ltd	Novel compounds
WO2021072212A1 (fr) *	2019-10-11	2021-04-15	Mayo Foundation For Medical Education And Research	Inhibiteurs de protéasome
EP4139289A1 (fr) *	2020-04-21	2023-03-01	University of Rochester	Inhibiteurs de la protéine epididymus humaine 4
US20250295771A1 (en)	2022-05-11	2025-09-25	Celgene Corporation	Methods and uses related to t cell therapy and production of same
WO2023220655A1 (fr)	2022-05-11	2023-11-16	Celgene Corporation	Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
TW202430548A (zh)	2022-09-29	2024-08-01	日商武田藥品工業股份有限公司	Ｃｄ３８結合融合蛋白組合療法
WO2024097905A1 (fr)	2022-11-02	2024-05-10	Celgene Corporation	Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur
CN116768972A (zh) *	2023-06-25	2023-09-19	重庆药友制药有限责任公司	一种卡非佐米中间体的制备方法
WO2025035020A2 (fr)	2023-08-09	2025-02-13	Amgen Inc.	Méthodes d'utilisation du carfilzomib
EP4685151A1 (fr)	2024-07-24	2026-01-28	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibiteur du protéasome

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US569748A (en)		1896-10-20		Henry edmunds
US4733665C2 (en)	1985-11-07	2002-01-29	Expandable Grafts Partnership	Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5071957A (en)	1989-08-04	1991-12-10	Bristol-Myers Company	Antibiotic BU-4061T
US4990448A (en)	1989-08-04	1991-02-05	Bristol-Myers Company	Bu-4061T
US5340736A (en)	1991-05-13	1994-08-23	The President & Fellows Of Harvard College	ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU4499697A (en)	1996-09-13	1998-04-02	New York University	Method for treating parasitic diseases with proteasome inhibitors
US6099851A (en) *	1998-06-02	2000-08-08	Weisman; Kenneth M.	Therapeutic uses of leuprolide acetate
US6902721B1 (en)	1998-07-10	2005-06-07	Osteoscreen, Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en)	1998-07-10	2002-10-08	Osteoscreen, Inc.	Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en)	1998-07-10	2005-01-04	Osteoscreen Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en)	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
US6492333B1 (en)	1999-04-09	2002-12-10	Osteoscreen, Inc.	Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en)	1999-05-12	2004-12-14	Yale University	Enzyme inhibition
EP1477180A1 (fr)	1999-10-20	2004-11-17	Osteoscreen, Inc.	Inhibiteurs de l'activité de proteasome pour favoriser la croissance osseuse et la pousse des cheveux
JP4412586B2 (ja)	2002-01-08	2010-02-10	エーザイ・アール・アンド・ディー・マネジメント株式会社	エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
WO2005105827A2 (fr) *	2004-04-15	2005-11-10	Proteolix, Inc.	Composes pour l'inhibition enzymatique
US7232818B2 (en) *	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
US20050256324A1 (en)	2004-05-10	2005-11-17	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
US8088741B2 (en)	2004-05-10	2012-01-03	Onyx Therapeutics, Inc.	Compounds for enzyme inhibition

2005
- 2005-04-14 US US11/106,879 patent/US7232818B2/en not_active Expired - Lifetime
- 2005-08-08 ES ES10012498.1T patent/ES2525248T3/es not_active Expired - Lifetime
- 2005-08-08 AT AT05784484T patent/ATE496062T1/de active
- 2005-08-08 DK DK05784484.7T patent/DK1781688T3/da active
- 2005-08-08 ES ES16166492.5T patent/ES2674277T3/es not_active Expired - Lifetime
- 2005-08-08 JP JP2007525077A patent/JP4743720B2/ja not_active Expired - Lifetime
- 2005-08-08 KR KR1020137016063A patent/KR20130080064A/ko not_active Withdrawn
- 2005-08-08 EP EP10012498.1A patent/EP2266999B1/fr not_active Expired - Lifetime
- 2005-08-08 AU AU2005271232A patent/AU2005271232B2/en active Active
- 2005-08-08 PL PL05784484T patent/PL1781688T3/pl unknown
- 2005-08-08 LT LTEP16166492.5T patent/LT3101026T/lt unknown
- 2005-08-08 BR BRPI0514102A patent/BRPI0514102B8/pt active IP Right Grant
- 2005-08-08 SG SG10201701794UA patent/SG10201701794UA/en unknown
- 2005-08-08 US US11/199,899 patent/US7417042B2/en active Active
- 2005-08-08 WO PCT/US2005/028246 patent/WO2006017842A1/fr not_active Ceased
- 2005-08-08 KR KR1020127030701A patent/KR101544258B1/ko not_active Expired - Lifetime
- 2005-08-08 PT PT161664925T patent/PT3101026T/pt unknown
- 2005-08-08 SI SI200531264T patent/SI1781688T1/sl unknown
- 2005-08-08 PL PL16166492T patent/PL3101026T3/pl unknown
- 2005-08-08 HU HUE16166492A patent/HUE038005T2/hu unknown
- 2005-08-08 PT PT05784484T patent/PT1781688E/pt unknown
- 2005-08-08 BR BR122020008634A patent/BR122020008634B8/pt active IP Right Grant
- 2005-08-08 EP EP16166492.5A patent/EP3101026B1/fr not_active Expired - Lifetime
- 2005-08-08 EP EP05784484A patent/EP1781688B1/fr not_active Expired - Lifetime
- 2005-08-08 CN CN201110145272.7A patent/CN102286070B/zh not_active Expired - Lifetime
- 2005-08-08 SG SG200905204-4A patent/SG155187A1/en unknown
- 2005-08-08 SI SI200532211T patent/SI3101026T1/en unknown
- 2005-08-08 CA CA2589765A patent/CA2589765C/fr not_active Expired - Lifetime
- 2005-08-08 DK DK16166492.5T patent/DK3101026T3/en active
- 2005-08-08 DE DE602005026019T patent/DE602005026019D1/de not_active Expired - Lifetime
- 2005-08-08 EP EP10012497.3A patent/EP2270026B1/fr not_active Expired - Lifetime
- 2005-08-08 KR KR1020077003533A patent/KR101354280B1/ko not_active Expired - Lifetime
- 2005-08-08 IL IL181127A patent/IL181127A/en active Protection Beyond IP Right Term
2007
- 2007-02-20 NO NO20070965A patent/NO341015B1/no unknown
- 2007-04-11 US US11/786,217 patent/US7491704B2/en not_active Expired - Lifetime
2011
- 2011-03-04 JP JP2011047047A patent/JP5394423B2/ja not_active Expired - Lifetime
- 2011-04-04 CY CY20111100347T patent/CY1116771T1/el unknown
2012
- 2012-08-22 IL IL221572A patent/IL221572B/en active IP Right Grant
2014
- 2014-08-06 US US14/452,844 patent/US20140342977A1/en not_active Abandoned
2015
- 2015-08-26 US US14/835,876 patent/US20150361134A1/en not_active Abandoned
2016
- 2016-04-05 HU HUS1600014C patent/HUS1600014I1/hu unknown
- 2016-04-06 LU LU93015C patent/LU93015I2/fr unknown
- 2016-04-08 US US15/094,088 patent/US20160222057A1/en not_active Abandoned
- 2016-04-12 LT LTPA2016010C patent/LTC1781688I2/lt unknown
- 2016-04-22 CY CY2016009C patent/CY2016009I1/el unknown
- 2016-05-12 FR FR16C0017C patent/FR16C0017I2/fr active Active
2017
- 2017-03-14 NO NO20170381A patent/NO344397B1/no unknown
2018
- 2018-02-13 US US15/895,120 patent/US20180170962A1/en not_active Abandoned
- 2018-06-20 CY CY181100642T patent/CY1120677T1/el unknown
- 2018-09-20 IL IL261892A patent/IL261892B/en active IP Right Grant
2019
- 2019-03-13 US US16/351,669 patent/US20190211058A1/en not_active Abandoned
- 2019-10-31 US US16/669,601 patent/US20200071356A1/en not_active Abandoned
2020
- 2020-06-26 US US16/912,806 patent/US20200325172A1/en not_active Abandoned
2021
- 2021-02-08 US US17/169,990 patent/US20210179663A1/en not_active Abandoned
2022
- 2022-04-29 US US17/733,077 patent/US20220267372A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP4743720B2 (ja)	2011-08-10
ES2674277T3 (es)	2018-06-28
US20190211058A1 (en)	2019-07-11
EP1781688A1 (fr)	2007-05-09
KR20130080064A (ko)	2013-07-11
KR20070047780A (ko)	2007-05-07
EP2270026B1 (fr)	2016-05-18
IL261892B (en)	2019-12-31
US20060030533A1 (en)	2006-02-09
US20050245435A1 (en)	2005-11-03
US7232818B2 (en)	2007-06-19
IL221572A0 (en)	2012-10-31
CY2016009I2 (el)	2016-08-31
JP5394423B2 (ja)	2014-01-22
DK3101026T3 (en)	2018-06-18
CY1116771T1 (el)	2016-08-31
EP2270026A2 (fr)	2011-01-05
BR122020008634B1 (pt)	2021-02-17
EP3101026A1 (fr)	2016-12-07
HK1103525A1 (en)	2007-12-21
BRPI0514102B1 (pt)	2020-07-07
CY1120677T1 (el)	2019-12-11
US20200071356A1 (en)	2020-03-05
FR16C0017I2 (fr)	2016-08-26
IL181127A (en)	2013-03-24
NO344397B1 (no)	2019-11-25
HK1231491A1 (en)	2017-12-22
US7417042B2 (en)	2008-08-26
ATE496062T1 (de)	2011-02-15
US20160222057A1 (en)	2016-08-04
KR101354280B1 (ko)	2014-01-23
CA2589765A1 (fr)	2006-02-16
IL181127A0 (en)	2007-07-04
JP2011148805A (ja)	2011-08-04
KR20120135355A (ko)	2012-12-12
PL3101026T3 (pl)	2018-12-31
US20140342977A1 (en)	2014-11-20
HK1152716A1 (en)	2012-03-09
US7491704B2 (en)	2009-02-17
BR122020008634B8 (pt)	2021-07-27
IL221572B (en)	2018-10-31
AU2005271232B2 (en)	2012-07-05
AU2005271232A1 (en)	2006-02-16
KR101544258B1 (ko)	2015-08-21
LU93015I2 (fr)	2016-06-06
WO2006017842A1 (fr)	2006-02-16
ES2525248T3 (es)	2014-12-19
EP1781688B1 (fr)	2011-01-19
EP2270026A3 (fr)	2011-09-14
CA2589765C (fr)	2015-06-30
LTC1781688I2 (lt)	2017-09-25
US20180170962A1 (en)	2018-06-21
US20070191284A1 (en)	2007-08-16
EP2266999A3 (fr)	2011-09-14
PT1781688E (pt)	2011-04-05
PT3101026T (pt)	2018-08-03
NO341015B1 (no)	2017-08-07
EP2266999A2 (fr)	2010-12-29
FR16C0017I1 (fr)	2016-06-24
DK1781688T3 (da)	2011-03-14
DE602005026019D1 (de)	2011-03-03
SI1781688T1 (sl)	2011-05-31
LT3101026T (lt)	2018-07-10
NO20170381A1 (no)	2007-04-16
NO20070965L (no)	2007-04-16
HUS1600014I1 (hu)	2016-05-30
SG10201701794UA (en)	2017-04-27
PL1781688T3 (pl)	2011-06-30
EP3101026B1 (fr)	2018-03-28
US20220267372A1 (en)	2022-08-25
CY2016009I1 (el)	2016-08-31
HK1152536A1 (en)	2012-03-02
EP2266999B1 (fr)	2014-09-24
HUE038005T2 (hu)	2018-09-28
BRPI0514102B8 (pt)	2021-05-25
US20150361134A1 (en)	2015-12-17
LTPA2016010I1 (lt)	2016-04-25
SI3101026T1 (en)	2018-08-31
BRPI0514102A (pt)	2008-05-27
CN102286070B (zh)	2014-12-10
JP2008509166A (ja)	2008-03-27
CN102286070A (zh)	2011-12-21
US20200325172A1 (en)	2020-10-15
US20210179663A1 (en)	2021-06-17
IL261892A (en)	2018-10-31

Publication	Publication Date	Title
HUS1600014I1 (hu)	2016-05-30	Vegyületek proteasztómális enzimek gátlására
IL217210A0 (en)	2012-01-31	Compounds for proteasome enzyme inhibition
EP2564834A3 (fr)	2013-08-21	Composés pour lýinhibition dýune enzyme du protéasome
MY145757A (en)	2012-04-13	Compounds for enzyme inhibition
WO2008140782A3 (fr)	2008-12-31	Composés d'inhibition enzymatique
WO2006045066A3 (fr)	2006-08-31	Composes pour inhibition d'enzymes
CR9962A (es)	2008-10-17	Compuestos para inhibicion enzimatica